Payment overview · 2025
General Payments
$2,584.55
133 reported records · 31 companies
Healthcare provider profile · identity verified
David French
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · HOUSTON, TX · NPI 1730619826
Verified facts
What the public records show
CMS Open Payments records show David French received $2,584.55 in general payments during 2025 across 133 reported records.
ABBVIE INC. accounted for 22.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 37 associated products.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Nuedexta by this doctor in 2024.
SK Life Science, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XCOPRI as an associated drug or biological on 1992 records involving 782 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Xcopri by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $591.52 | 22.9% | 33 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $222.98 | 8.6% | 14 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $220.95 | 8.6% | 9 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $169.09 | 6.5% | 9 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $162.57 | 6.3% | 8 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $146.93 | 5.7% | 8 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $105.01 | 4.1% | 1 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $90.38 | 3.5% | 5 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $75.70 | 2.9% | 4 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $73.18 | 2.8% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $69.32 | 2.7% | 4 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $66.41 | 2.6% | 3 | 2025 |
| LivaNova USA, Inc. | Unresolved — no canonical attribution shown | $58.39 | 2.3% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $56.34 | 2.2% | 3 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $48.64 | 1.9% | 3 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $47.65 | 1.8% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $42.21 | 1.6% | 2 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $41.61 | 1.6% | 2 | 2025 |
| Tanabe Pharma America, Inc. | Unresolved — no canonical attribution shown | $37.22 | 1.4% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $36.43 | 1.4% | 2 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $36.26 | 1.4% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $28.69 | 1.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $21.70 | 0.8% | 1 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$19.65 | 0.8% | 1 | 2025 |
| Sonex Health, Inc. | Unresolved — no canonical attribution shown | $19.56 | 0.8% | 2 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.80 | 0.7% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $16.91 | 0.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.33 | 0.6% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $15.94 | 0.6% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $15.59 | 0.6% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $13.59 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,526.06 | 132 |
| Education | $58.49 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $401.17 | 22 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $383.81 | 23 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $190.35 | 11 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $169.09 | 9 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $166.19 | 10 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $162.46 | 8 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $121.07 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $115.34 | 7 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $108.23 | 6 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $108.02 | 6 | 2025 |
Source payment records
|
|||||
| Mavenclad Normalized: mavenclad |
Drug | EMD Serono, Inc. | $105.01 | 1 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $90.38 | 5 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $75.70 | 4 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $73.18 | 4 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $66.41 | 3 | 2025 |
Source payment records
|
|||||
| Ocrevus Normalized: ocrevus |
Biological | Genentech USA, Inc. | $60.96 | 3 | 2025 |
Source payment records
|
|||||
| VNS THERAPY SENTIVA MODEL 1000 GENERATOR Normalized: vns therapy sentiva model 1000 generator |
Device | LivaNova USA, Inc. | $58.39 | 2 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $56.79 | 4 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $56.34 | 3 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $42.21 | 2 | 2025 |
Source payment records
|
|||||
| Radicava Normalized: radicava |
Drug | Tanabe Pharma America, Inc. | $37.22 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $36.43 | 2 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $28.69 | 1 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $21.70 | 1 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $21.11 | 1 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $20.50 | 1 | 2025 |
Source payment records
|
|||||
| SX-ONE MICROKNIFE Normalized: sx one microknife |
Device | Sonex Health, Inc. | $19.56 | 2 | 2025 |
Source payment records
|
|||||
| Enspryng Normalized: enspryng |
Biological | Genentech USA, Inc. | $19.46 | 1 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $19.23 | 2 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $17.80 | 1 | 2025 |
Source payment records
|
|||||
| HORIZANT Normalized: horizant |
Drug | Azurity Pharmaceuticals, Inc. | $17.71 | 1 | 2025 |
Source payment records
|
|||||
| ZEMBRACE SYMTOUCH Normalized: zembrace symtouch |
Drug | Tonix Medicines, Inc. | $16.91 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $16.33 | 1 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $15.94 | 1 | 2025 |
Source payment records
|
|||||
| ELYXYB - CELECOXIB Normalized: elyxyb celecoxib |
Drug | SCILEX PHARMACEUTICALS INC. | $15.59 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $15.59 | 1 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $13.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| SK Life Science, Inc. Exact reporting entity; no affiliate inference |
2025 | XCOPRI open payments reported associated product |
CMS Open Payments — General Payments 1992 supporting records · 782 recipient NPIs · example record 1252276115 |
Xcopri · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Donepezil Hcl | Donepezil Hcl | 502 | 158 |
| Gabapentin | Gabapentin | 370 | 107 |
| Memantine Hcl | Memantine Hcl | 268 | 79 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 191 | 50 |
| Pregabalin | Pregabalin | 159 | 37 |
| Topiramate | Topiramate | 100 | 32 |
| Valproic Acid | Valproic Acid | 82 | 22 |
| Levetiracetam | Levetiracetam | 77 | 22 |
| Oxcarbazepine | Oxcarbazepine | 71 | 14 |
| Primidone | Primidone | 71 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 68 | 16 |
| Trazodone Hcl | Trazodone Hcl | 68 | 19 |
| Baclofen | Baclofen | 49 | 12 |
| Propranolol Hcl | Propranolol Hcl | 46 | 14 |
| Propranolol Hcl Er | Propranolol Hcl | 44 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 43 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 41 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 36 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 34 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 32 | 12 |
| Amantadine | Amantadine Hcl | 28 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | 11 |
| Sertraline Hcl | Sertraline Hcl | 27 | 11 |
| Lacosamide | Lacosamide | 25 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | 14 |
| Clonazepam | Clonazepam | 21 | suppressed |
| Xcopri | Cenobamate | 19 | suppressed |
| Adlarity | Donepezil Hcl | 18 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Kesimpta Pen | Ofatumumab | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Phenobarbital | Phenobarbital | 16 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 16 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 15 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 14 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 14 | suppressed |
| Austedo | Deutetrabenazine | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 12 | suppressed |
| Galantamine Er | Galantamine Hbr | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,584.55 · 133 records | ABBVIE INC. | AUSTEDO XR, BOTOX, BRIUMVI, Briviact, CREXONT, DAYBUE, ELYXYB - CELECOXIB, Enspryng, HORIZANT, INGREZZA, KESIMPTA, KISUNLA, Leqembi, Mavenclad, NURTEC ODT, Nayzilam, OCTAGAM IMMUNE GLOBULIN (HUMAN), Ocrevus, Ocrevus Zunovo, PANZYGA, PONVORY, PROCLAIM, QULIPTA, REXULTI, Radicava, SX-ONE MICROKNIFE, UBRELVY, UPLIZNA, VNS THERAPY SENTIVA MODEL 1000 GENERATOR, VUMERITY, VYEPTI, VYVGART HYTRULO, WaveWriter Alpha Prime 16, ZAVZPRET, ZEMBRACE SYMTOUCH, ZEPOSIA, ZTLido | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Otsuka America Pharmaceutical, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error